Table 1.
Demographics and Clinical and Immunologic Responses for Each Patient
| Patient ID | Age (years) | Sex | Tumor Type | Histology, Resection Extent | Chemotherapy* | ELISPOT Responses |
Best Response | Pseudoprogression | OS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-13Rα2 | EphA2 | Survivin | Tet | |||||||||
| 1 | 9.0 | F | BSG | None | NA | NA | NA | NA | PD | 8.3 | ||
| 2 | 13.6 | F | BSG | None | NA | NA | NA | NA | PD | 8.6 | ||
| 3 | 6.1 | F | BSG | None | 68 | 14 | 2 | 1,480 | SD | 9.6 | ||
| 4 | 7.1 | F | BSG | None | 846 | 140 | 322 | 560 | SD | Yes | 18.4 | |
| 5 | 5.6 | F | BSG | None | 22 | 12 | 14 | 534 | SD | 13.0 | ||
| 6 | 7.3 | F | HGG | GBM, STR | TMZ | 742 | 256 | 42 | 456 | SD | 10.8 | |
| 7 | 7.2 | M | BSG | SAHA | 474 | 340 | 6 | 396 | SD | 15.7 | ||
| 8 | 9.6 | M | HGG | GBM, GTR | TMZ | 78 | 102 | 26 | 182 | CCR | 25.1 | |
| 9 | 5.2 | M | BSG | None | 14 | 180 | 4 | 162 | SD | 10.9 | ||
| 10 | 7.8 | F | BSG | None | 24 | 26 | 38 | 208 | SD | Yes | 19.5 | |
| 11 | 10.2 | F | BSG | None | 248 | 28 | 6 | 84 | PR | Yes | 19.5 | |
| 12 | 17.9 | M | BSG | None | 344 | 188 | 314 | 0 | SD | Yes | 11.3 | |
| 13 | 16.6 | M | HGG | GBM, STR | TMZ | 240 | 138 | 42 | 2 | PR | 20.3 | |
| 14 | 4.7 | M | BSG | AA, biopsy | TMZ | 18 | 72 | 30 | 348 | SD | Yes | > 38.0 |
| 15 | 3.3 | M | BSG | TMZ | 0 | 4 | 0 | 32 | SD | 23.0 | ||
| 16 | 3.1 | M | BSG | 0 | AF | AF | AF | AF | SD | 23.6 | ||
| 17 | 2.2 | M | BSG | Bev | 16 | 8 | 12 | 10 | SD | 13.3 | ||
| 18 | 9.3 | M | BSG | TMZ | 10 | 64 | 34 | 18 | SD | 8.5 | ||
| 19 | 11.7 | M | HGG | AA, biopsy | TMZ | 54 | 84 | 74 | 28 | MR | 26.0 | |
| 20 | 7.8 | M | BSG | TMZ | 24 | 44 | 40 | 34 | SD | 6.3 | ||
| 21 | 4.4 | F | BSG | None | 18 | 12 | 14 | 0 | SD | 17.5 | ||
| 22 | 9.2 | F | BSG | None | 26 | 26 | 42 | 8 | SD | 12.4 | ||
| 23 | 9.7 | F | BSG | None | 608 | 60 | 30 | 222 | SD | 13.6 | ||
| 24 | 16.1 | F | BSG | None | 2 | 10 | 0 | 66 | SD | 10.0 | ||
| 25 | 13.6 | M | HGG | GBM, GTR | TMZ | PA | PA | PA | PA | CCR | > 14.7 | |
| 26 | 11.5 | F | HGG | GBM, biopsy | TMZ | PA | PA | PA | PA | SD | > 13.1 | |
NOTE. Results of maximal interferon gamma enzyme-linked immunosorbent spot (ELISPOT) reactivity (net spots per 105 cells after background subtraction) are shown for each peptide epitope. Values ≥ 50 were considered positive and, in all but one instance, they reflected a two-fold increase compared with prevaccine. The sole exception, patient 10, responded strongly to tetanus toxoid at baseline so did not fulfill the criterion for a two-fold increase. Positive responses are shown in bold. NA indicates that samples were not available because of early progression before week 6.
Abbreviations: AA, anaplastic astrocytoma; AF, assay failure; Bev, bevacizumab; BSG, brainstem glioma; CCR, continued complete response (ie, prolonged disease-free status after surgical resection); GBM, glioblastoma; GTR, gross total resection; HGG, high-grade glioma; ID, identification number; IL-13Rα2, interleukin-13 receptor α2; MR, minor response; OS, overall survival; PA, pending analysis; PD, progressive disease; PR, partial response; SAHA, suberoylanilide hydroxamic acid; SD, stable disease; STR, subtotal resection; Tet, tetanus toxoid; TMZ, temozolomide.
Chemotherapy was administered concurrently with irradiation.